Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3424513 | 0.93 | S1PR1 (0.80) | S1PR1S1PR5 | |
| SCHEMBL2134665 | 0.88 | S1PR1 (0.75) | S1PR1S1PR5 | |
| SCHEMBL2124847 | 0.88 | S1PR1 (0.75) | S1PR1S1PR5 | |
| Formic Acid SCHEMBL2122592 | 0.86 | S1PR1 (0.72) | S1PR1S1PR5 | |
| Formic Acid SCHEMBL2122620 | 0.86 | S1PR1 (0.72) | S1PR1S1PR5 | |
| SCHEMBL2125026 | 0.86 | S1PR1 (1.00) | S1PR1S1PR5 | |
| SCHEMBL2122625 | 0.86 | S1PR1 (0.71) | S1PR1S1PR5 | |
| SCHEMBL2122596 | 0.86 | S1PR1 (0.71) | S1PR1S1PR5 | |
| Hydrochloric Acid SCHEMBL2122860 | 0.85 | S1PR1 (0.98) | S1PR1S1PR5 | |
| SCHEMBL2124506 | 0.84 | S1PR1 (0.83) | S1PR1S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101086-A1 | THIADIAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF DISORDERS MEDIATED BY S1P1 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | claimed |
| US-20120101086-A1 | THIADIAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF DISORDERS MEDIATED BY S1P1 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101086-A1 | THIADIAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF DISORDERS MEDIATED BY S1P1 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101086-A1 | THIADIAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF DISORDERS MEDIATED BY S1P1 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| WO-2010146104-A1 | THIADIAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF DISORDERS MEDIATED BY SLPL RECEPTORS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101086-A1 | THIADIAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF DISORDERS MEDIATED BY S1P1 RECEPTORS | S1PR1, S1PR3, S1PR5 | S1PR1 1/4885S1PR5 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.